
Seroquel XR
Quetiapine
- SKU
- 0310-0283
- Mfr
- AstraZeneca Pharmaceuticals LP
60 tablet, extended release in 1 bottle
$1,648.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
1 Schizophrenia SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. 1) ].
- Strength
- Quetiapine Fumarate 300 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Extended Release
- Route
- Oral
Pharmacologic class
- Atypical AntipsychoticEstablished class
- Brand name
- Seroquel XR
- Generic name
- Quetiapine
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Product NDC (SKU)
- 0310-0283
- Active ingredients
- Quetiapine Fumarate 300 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA022047
- Marketed since
- July 16, 2007
- Label revised
- January 22, 2025
| Package NDC | Description |
|---|---|
| 0310-0283-60 | 60 TABLET, EXTENDED RELEASE in 1 BOTTLE |
Reading this NDC
0310-0283-60
- 01Labeler code
- AstraZeneca Pharmaceuticals LP
- 02Product code
- Seroquel XR, tablet, extended release
- 03Package code
- 60 tablet, extended release in 1 bottle
The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2A (5HT 2A ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2, but greater activity at 5HT 2A receptors, than the parent drug (quetiapine).
Warning: Increased mortality in elderly patients with dementia-related psychosis; and suicidal thoughts and behaviors
Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions
]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions
]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions
]. SEROQUEL XR is not approved for use in pediatric patients under ten years of age [see Use in Specific Populations
]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SEROQUEL XR is not approved for elderly patients with dementia-related psychosis.
Suicidal Thoughts and Behaviors
- Increased risk of suicidal thoughts and behavior in children, adolescents and young adults taking antidepressants.
- Monitor for worsening and emergence of suicidal thoughts and behaviors.
SEROQUEL XR is an atypical antipsychotic indicated for the treatment of:
- Schizophrenia
- Bipolar I disorder, manic, or mixed episodes
- Bipolar disorder, depressive episodes
- Major depressive disorder, adjunctive therapy with antidepressants
Schizophrenia SEROQUEL
XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL [see Clinical Studies
].
Bipolar Disorder SEROQUEL
XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 - 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL [see Clinical Studies
]. SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies
]. SEROQUEL XR is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with bipolar I disorder treated with SEROQUEL. The effectiveness of monotherapy for the maintenance treatment of bipolar I disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies
].
Adjunctive
Treatment of Major Depressive Disorder (MDD) SEROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment [see Clinical Studies
].
Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder
Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment.
Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.
Read before you order

Mental health · 2 min read
Lithium, aripiprazole and quetiapine: why monitoring matters
How lithium and atypical antipsychotics work, the blood tests they need and the warning signs of lithium toxicity.

Mental health · 2 min read
Starting an SSRI: what to expect from sertraline and escitalopram
How SSRI antidepressants work, why they take weeks to help, common early side effects and how to stop them safely.

Mental health · 2 min read
Bupropion and other non-SSRI antidepressants
How bupropion differs from SSRIs, why it is less likely to cause sexual side effects or weight gain, and who should avoid it.
More in Psychotropic
View all
Generic · Solution
Aripiprazole
Aripiprazole 1 mg/mL
- SKU
- 60505-0404
- Mfr
- Apotex Corp.
From $80.99Min. 4 packs

Generic · Tablet
Aripiprazole
Aripiprazole 5 mg/1
- SKU
- 43598-966
- Mfr
- Dr.Reddys Laboratories Inc
From $4.99Min. 61 packs

Generic · Tablet
Aripiprazole
Aripiprazole 20 mg/1
- SKU
- 50090-6403
- Mfr
- A-S Medication Solutions
From $7.99Min. 38 packs

Generic · Tablet
Aripiprazole
Aripiprazole 30 mg/1
- SKU
- 72865-158
- Mfr
- XLCare Pharmaceuticals, Inc.
From $7.99Min. 38 packs